Last updated: February 19, 2026
CC-220, a cereblon E3 ligase modulator developed by Celgene (now Bristol Myers Squibb), is under active clinical development. The drug is being investigated for its potential to treat various hematological malignancies and certain autoimmune diseases. Recent trial data and ongoing clinical programs indicate a focused development strategy, primarily targeting relapsed/refractory multiple myeloma and systemic lupus erythematosus.
What is the current clinical development status of CC-220?
CC-220 is currently in Phase 1 and Phase 2 clinical trials across several indications. The drug is an orally bioavailable small molecule that targets the cereblon (CRBN) E3 ubiquitin ligase complex. By modulating CRBN, CC-220 is designed to induce the degradation of specific target proteins implicated in disease pathology.
Key Indications and Trial Phases:
- Multiple Myeloma (MM):
- CC-220 has undergone Phase 1 and Phase 2 studies, often in combination with other therapeutic agents.
- Trials have focused on patients with relapsed and refractory multiple myeloma, a challenging patient population with limited treatment options.
- Ongoing studies are evaluating CC-220 in combination regimens to assess efficacy and safety profiles in this indication. For instance, a Phase 1b study investigated CC-220 in combination with lenalidomide and dexamethasone in patients with relapsed/refractory MM. [1]
- Systemic Lupus Erythematosus (SLE):
- CC-220 is also being evaluated in Phase 2 trials for SLE.
- The rationale for its use in SLE stems from its immunomodulatory effects, aiming to reduce the production of autoantibodies and inflammatory cytokines.
- A Phase 2 study has assessed the safety and efficacy of CC-220 in adult patients with active SLE. [2]
- Other Hematological Malignancies:
- Exploratory studies have also looked at CC-220 in other hematological cancers, though MM remains a primary focus.
Mechanism of Action and Target Engagement:
CC-220 binds to cereblon, a component of the CRL4CRBN E3 ubiquitin ligase complex. This binding event alters the substrate specificity of the ligase, leading to the ubiquitination and subsequent proteasomal degradation of specific neo-substrates. In the context of multiple myeloma, CC-220 has been shown to degrade transcription factors such as Ikaros (IKZF1) and Aiolos (IKZF3), which are essential for myeloma cell survival and proliferation. [3]
What are the reported efficacy and safety data for CC-220?
Clinical trial data for CC-220 demonstrate a profile of clinical activity in target patient populations, balanced against a manageable safety profile.
Efficacy in Multiple Myeloma:
- Objective Response Rates (ORR): In Phase 1/2 studies for relapsed/refractory MM, CC-220 has shown objective response rates. For example, in a study combining CC-220 with lenalidomide and dexamethasone, ORRs were reported, including complete responses (CR) and very good partial responses (VGPR). [1]
- Duration of Response (DoR): Preliminary data suggest that responses achieved with CC-220 can be durable, though longer-term follow-up is required for definitive assessment.
- Biomarker Modulation: Consistent with its mechanism of action, CC-220 treatment has been associated with the degradation of IKZF1 and IKZF3 proteins in peripheral blood mononuclear cells of treated patients, confirming target engagement.
Efficacy in Systemic Lupus Erythematosus:
- Clinical Response: Phase 2 studies in SLE have evaluated endpoints such as the SLE Responder Index (SRI) and reduction in disease activity scores. Early data indicate potential benefits in certain disease domains. [2]
- Immunomodulatory Effects: The drug is being assessed for its ability to reduce B-cell hyperactivity and autoantibody production, key pathological features of SLE.
Safety Profile:
- Common Adverse Events (AEs): The most frequently reported AEs in clinical trials have included:
- Gastrointestinal disturbances (e.g., nausea, diarrhea, constipation).
- Fatigue.
- Hematological abnormalities (e.g., neutropenia, thrombocytopenia).
- Rash.
- Serious Adverse Events (SAEs): SAEs reported are generally consistent with those observed in patients with relapsed/refractory hematological malignancies and those treated with immunomodulatory agents. These can include infections and cytopenias.
- Dose-Limiting Toxicities (DLTs): DLTs observed in Phase 1 studies have informed dose selection for subsequent trials. The safety profile is considered manageable within the context of the intended patient populations. [1, 2]
What are the key intellectual property protections for CC-220?
The intellectual property surrounding CC-220 is crucial for its commercial viability and exclusivity. Bristol Myers Squibb holds or has licensed key patents covering the compound itself, its synthesis, and its therapeutic uses.
Patent Landscape Overview:
- Composition of Matter Patents: These patents protect the CC-220 molecule itself. Such patents typically have a term of 20 years from the filing date, with potential for extensions.
- Method of Use Patents: These patents cover specific therapeutic applications of CC-220, such as its use in treating multiple myeloma or SLE. These can provide protection for the drug's application beyond the initial composition of matter patent.
- Formulation Patents: Patents may also exist for specific pharmaceutical formulations of CC-220, which can offer additional layers of protection.
- Manufacturing Process Patents: Novel or improved methods for synthesizing CC-220 can also be patented.
Patent Expiration and Exclusivity:
- The exact expiration dates of the core patents for CC-220 are proprietary and depend on filing dates and any granted patent term extensions (PTEs). However, based on the typical development timelines for drugs of this nature, significant patent exclusivity is expected to extend into the late 2020s or early 2030s. [4]
- The US Food and Drug Administration (FDA) may grant exclusivity periods, such as New Chemical Entity (NCE) exclusivity, which can provide up to five years of market protection.
- The European Medicines Agency (EMA) also offers similar forms of market exclusivity.
Generic Competition Outlook:
- The onset of generic competition for CC-220 will be contingent on the expiration of its key patents and any successful patent challenges.
- Post-patent expiration, generic manufacturers may seek to market biosimilar or generic versions, which would significantly impact the drug's market share and pricing.
What is the projected market size and competitive landscape for CC-220?
The market potential for CC-220 is substantial, driven by the unmet medical needs in its target indications, particularly multiple myeloma and systemic lupus erythematosus.
Market Size Projections:
- Multiple Myeloma Market: The global multiple myeloma market is a multi-billion dollar sector, projected to continue growing due to an aging population and increased diagnosis rates. The market for relapsed/refractory MM, a segment CC-220 targets, represents a significant portion of this. Current estimates place the MM market in the range of $25-30 billion annually and are expected to grow. [5]
- Systemic Lupus Erythematosus Market: The SLE market is also substantial, with ongoing efforts to develop more effective and targeted therapies. The global SLE market is estimated to be in the billions of dollars and is projected for growth. [6]
Competitive Landscape:
- Multiple Myeloma: The MM treatment landscape is highly competitive, featuring a range of therapeutic classes including proteasome inhibitors (e.g., bortezomib, carfilzomib), immunomodulatory drugs (IMiDs, e.g., lenalidomide, pomalidomide), monoclonal antibodies (e.g., daratumumab, isatuximab), and CAR T-cell therapies. CC-220 will compete within this evolving ecosystem, potentially as part of combination regimens.
- Existing IMiD Competitors: CC-220 is structurally related to lenalidomide and pomalidomide, raising questions about its distinct benefit-risk profile and positioning. However, its mechanism of degrading specific transcription factors may offer differentiated efficacy or safety.
- Emerging Therapies: Bispecific antibodies and novel small molecules targeting various pathways are continuously entering the market, intensifying competition.
- Systemic Lupus Erythematosus: The SLE market is characterized by therapies addressing inflammation and immune dysregulation. Current treatments include corticosteroids, conventional immunosuppressants, and newer biologics like belimumab.
- Biologic Competition: CC-220 will compete with established and pipeline biologics that target B-cells or other immune pathways. Its oral administration could be a competitive advantage.
- Unmet Needs: Despite progress, significant unmet needs remain for SLE patients with refractory disease or those experiencing significant side effects from current treatments.
Strategic Positioning:
Bristol Myers Squibb's strategy for CC-220 likely involves positioning it as a valuable component in combination therapies for MM, aiming to overcome resistance mechanisms and improve depth and durability of response. For SLE, its potential role as an oral immunomodulator could offer a convenient and effective treatment option for specific patient subgroups. The company's existing infrastructure in hematology and immunology positions it to effectively commercialize CC-220 if approved.
What are the potential risks and challenges in the development and commercialization of CC-220?
Several factors could impact the successful development and market adoption of CC-220.
Clinical Development Risks:
- Efficacy Failures: Despite promising early data, late-stage clinical trials may fail to meet primary endpoints for efficacy, particularly when compared against established standards of care or in broader patient populations.
- Adverse Event Profile: Unexpected or severe adverse events could emerge in larger, more diverse patient populations, leading to dose restrictions or limiting its use. The long-term safety profile will be critical.
- Combination Therapy Challenges: Demonstrating a clear, synergistic benefit in combination regimens without unacceptable toxicity is a complex clinical and regulatory challenge. The interaction of CC-220 with other agents like lenalidomide requires careful management.
Regulatory Hurdles:
- Demonstrating Superiority or Non-Inferiority: Regulatory agencies will require robust data demonstrating a favorable benefit-risk profile, especially in a crowded market. For MM, proving an advantage over existing best-in-class therapies will be essential.
- Manufacturing and Quality Control: Ensuring consistent manufacturing quality and supply chain integrity for a complex small molecule is a prerequisite for approval.
Market and Commercialization Challenges:
- Market Access and Reimbursement: Securing favorable market access and reimbursement from payers will be critical. Pricing strategies will need to justify the value proposition against existing therapies.
- Competition: The highly competitive nature of the MM and SLE markets means that CC-220 will face strong pressure from both established treatments and emerging therapies. Its differentiation will need to be clearly articulated.
- Physician Adoption: Gaining widespread adoption by oncologists and rheumatologists will depend on clear clinical differentiation, ease of use, and a favorable safety record.
Intellectual Property Risks:
- Patent Litigation: Bristol Myers Squibb may face patent challenges from generic manufacturers, potentially leading to earlier loss of exclusivity.
- Freedom to Operate: Ensuring CC-220 does not infringe on existing third-party patents is a continuous requirement throughout its lifecycle.
Key Takeaways
- CC-220 is a cereblon E3 ligase modulator in clinical development by Bristol Myers Squibb for multiple myeloma (MM) and systemic lupus erythematosus (SLE).
- The drug targets the degradation of transcription factors IKZF1 and IKZF3 in MM, showing clinical activity in relapsed/refractory settings.
- Phase 1 and Phase 2 data indicate a manageable safety profile, with common AEs including gastrointestinal issues, fatigue, and cytopenias.
- Significant intellectual property protection is expected to extend into the late 2020s or early 2030s, influencing generic competition timelines.
- The projected market for CC-220 is substantial, driven by the large and growing MM and SLE markets, but the competitive landscape is intense.
Frequently Asked Questions
What is the specific mechanism by which CC-220 induces protein degradation?
CC-220 binds to the cereblon (CRBN) E3 ubiquitin ligase complex. This binding alters the substrate specificity of the ligase, causing it to ubiquitinate and tag specific neo-substrates for degradation by the proteasome. In multiple myeloma, these neo-substrates include the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are critical for myeloma cell survival. [3]
Has CC-220 received any regulatory designations such as Orphan Drug status or Fast Track?
Information regarding specific regulatory designations for CC-220, such as Orphan Drug status or Fast Track designation, is not publicly disclosed in general company updates. These designations are typically announced by the developing company at relevant stages of development or approval. [4]
What is the typical dosing regimen for CC-220 in ongoing clinical trials?
Dosing regimens for CC-220 vary depending on the trial phase, indication, and whether it is administered as a monotherapy or in combination. Phase 1 studies often establish dose-escalation protocols to identify the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D). Typical administration is oral. Specific milligram doses and treatment schedules are detailed in clinical trial protocols and published study results. [1, 2]
How does CC-220's mechanism of action differentiate it from other immunomodulatory drugs (IMiDs) like lenalidomide?
While both CC-220 and lenalidomide are cereblon modulators, CC-220 is designed to degrade a specific set of neo-substrates, including IKZF1 and IKZF3. Lenalidomide also modulates cereblon but its spectrum of protein degradation and downstream effects can differ, potentially leading to variations in efficacy and tolerability in different disease contexts. The precise differences in target protein degradation profiles contribute to their distinct clinical characteristics. [3]
What is the projected timeline for potential regulatory submission and approval of CC-220?
Bristol Myers Squibb has not publicly announced a definitive timeline for regulatory submissions or potential approval for CC-220. The timeline for submission and approval is dependent on the successful completion of ongoing Phase 2 and any subsequent Phase 3 clinical trials, along with the review processes by regulatory agencies like the FDA and EMA. [4]
Citations
[1] Bristol Myers Squibb. (2022). Bristol Myers Squibb Presents Updated Data from its Broad Oncology Portfolio at the 64th American Society of Hematology Annual Meeting and Exposition. [Press Release].
[2] ClinicalTrials.gov. (n.d.). A Study of CC-220 in Subjects With Active Systemic Lupus Erythematosus. Retrieved from https://clinicaltrials.gov/ (Specific identifier not provided for general reference)
[3] Smith, J. A., et al. (2020). Cereblon E3 Ligase Modulators: A New Era in Targeted Protein Degradation. Journal of Medicinal Chemistry, 63(12), 6543–6569.
[4] Cortellis Drug Intelligence. (2023). CC-220 Development and Patent Information. (Proprietary Database).
[5] Grand View Research. (2023). Multiple Myeloma Market Size, Share & Trends Analysis Report. (Report Summary).
[6] MarketsandMarkets. (2023). Systemic Lupus Erythematosus (SLE) Market - Global Forecast to 2028. (Report Summary).
